SCHEMBL24401671

SCHEMBL24401671

Cc1cccc(-c2nnc3ccc(Cl)nn23)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 11/20 0.54
KDM4E B2RXH2 4/20 0.50
HSD17B10 Q99714 3/20 0.50
ALDH1A1 P00352 3/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HPGD P15428 2/20 0.47
LMNA P02545 2/20 0.47
MAPT P10636 1/20 0.47
ALOX15 P16050 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
TSHR P16473 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
BRD4 O60885 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
ADORA2A P29274 1/20 0.46
ADORA2B P29275 1/20 0.46
ADORA1 P30542 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29617977 1.00 DPP4 (0.54) DPP4KDM4EHSD17B10ALDH1A1CYP1A2
SCHEMBL32665417 0.88 DYRK3 (0.58) DPP4KDM4EHSD17B10ALDH1A1CYP1A2
SCHEMBL12874554 0.85 DYRK3 (0.60) DPP4KDM4EHSD17B10ALDH1A1CYP1A2
SCHEMBL15365501 0.85 KDM4E (0.65) DPP4KDM4EHSD17B10ALDH1A1CYP1A2
SCHEMBL15365361 0.84 PIM1 (0.62) DPP4KDM4EHSD17B10ALDH1A1CYP1A2
SCHEMBL5620191 0.84 GRK5 (0.46) DPP4KDM4EHSD17B10ALDH1A1CYP1A2
SCHEMBL32665401 0.84 PIM1 (0.62) DPP4KDM4EHSD17B10ALDH1A1CYP1A2
SCHEMBL4784567 0.83 BRD4 (0.65) KDM4EHSD17B10ALDH1A1SMN1; SMN2HPGD
SCHEMBL16456325 0.82 KDM4E (0.55) KDM4EHSD17B10ALDH1A1CYP1A2CYP2C9
SCHEMBL937211 0.81 KDM4E (0.44) KDM4EHSD17B10ALDH1A1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022093919-A1 INHIBITORS OF EXO1 IN COMBINATION WITH OTHER CANCER DRUGS TO INHIBIT CANCER CELLS DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-05-05 WO disclosed